Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -27.16%43 Return-on-Tangible-Equity is 9.01% as of Apr. 2026, which is 268% above its 10-year median of 2.45. GuruFocus rates PBSV with a GF Score™ of 43/100 and a GF Value™ of $0.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 576 Healthcare Providers & Services companies, Pharma-Bio Serv ranks worse than 74.48% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Pharma-Bio Serv's annualized net income for the quarter that ended in Apr. 2026 was $0.93 Mil. Pharma-Bio Serv's average shareholder tangible equity for the quarter that ended in Apr. 2026 was $10.35 Mil. Therefore, Pharma-Bio Serv's annualized Return-on-Tangible-Equity for the quarter that ended in Apr. 2026 was 9.01%.
The historical rank and industry rank for Pharma-Bio Serv's Return-on-Tangible-Equity or its related term are showing as below:
PBSV'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -10.04 Med: 2.45 Max: 10.21
Current: 0.55
During the past 13 years, Pharma-Bio Serv's highest Return-on-Tangible-Equity was 10.21%. The lowest was -10.04%. And the median was 2.45%.
PBSV's Return-on-Tangible-Equity is ranked worse than 74.48% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.575
vs PBSV: 0.55
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Pharma-Bio Serv Return-on-Tangible-Equity Related Terms
Pharma-Bio Serv Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBSV vs MGRX, BFRG, VYND: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Pharma-Bio Serv's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.01% mean?
Pharma-Bio Serv (PBSV) has a Return-on-Tangible-Equity of 9.01% as of Apr. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pharma-Bio Serv and its competitors. This is 268% above median its historical median of 2.45. According to the industry distribution chart, Pharma-Bio Serv ranks #429 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 74.5%.
Is Pharma-Bio Serv's Return-on-Tangible-Equity too high?
Pharma-Bio Serv's current Return-on-Tangible-Equity of 9.01% is 268% above median its 10-year median of 2.45. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.58. Pharma-Bio Serv's value of 9.01% is 14.8% below this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #429 out of 576 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Pharma-Bio Serv has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's Return-on-Tangible-Equity compare to MGRX and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #429 out of 576 companies for Return-on-Tangible-Equity. This places Pharma-Bio Serv in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.58. Pharma-Bio Serv's value of 9.01% is 14.8% below this benchmark. While the company's 10-year median is 2.45 vs. the industry median of 10.58, Pharma-Bio Serv has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.58, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current Return-on-Tangible-Equity of 9.01% is 14.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current Return-on-Tangible-Equity is 9.01%, which is 268% above median its own 10-year median of 2.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.58, compared to a current price of $0.42 — trading 27.2% below its estimated fair value. The current Return-on-Tangible-Equity is 9.01%, which is 268% above median its 10-year median of 2.45 and 14.8% below the Healthcare Providers & Services industry median of 10.58. Pharma-Bio Serv's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current Return-on-Tangible-Equity is 9.01% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.42 is trading 27.2% below its estimated GF Value™ of $0.58.
GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.
Key valuation signals for PBSV:
Return-on-Tangible-Equity: 9.01% (268% above median its 10-year median of 2.45)
GF Value™: $0.58 vs. price of $0.42 (27.2% below fair value)
Industry Position: 14.8% below the Healthcare Providers & Services median (#429 of 576)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
43GF Score
Get the complete analysis for PBSV
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
